Categories
Change Password!
Reset Password!
Montelukast + Levocetirizine markedly reduces daytime and nighttime nasal symptoms while minimizing adverse events and boosting patient satisfaction, making it the preferred choice for pediatric perennial allergic rhinitis.
In a randomized controlled study, a fixed-dose combination of Montelukast and Levocetirizine offered better symptom relief for children suffering from perennial allergic rhinitis (AR) than Montelukast monotherapy. The study, conducted with 147 children aged 6 to 14 years, investigated the efficacy and safety of the combination therapy for perennial AR management.
Participants were randomly allocated to either the combination group (5 mg Montelukast + 5 mg Levocetirizine) or the Montelukast group (5 mg Montelukast) for 4 weeks. Volunteers tracked their daytime nasal symptom score (DNSS) and nighttime nasal symptom score (NNSS) in a diary. Adverse events were recorded, and patient satisfaction with the therapy was also determined.
When DNSS and NNSS were examined separately, the combination group illustrated a greater reduction in daytime nasal congestion scores over the 4-week period when compared to Montelukast alone group (P = 0.0341). Specifically, daytime rhinorrhea symptom scores improved more in the combination therapy group (P = 0.0469). Nighttime nasal congestion scores also depicted greater improvement in the combination group (P = 0.0381).
Additionally, quality of life scores were quite better for those receiving combination therapy (P < 0.0001), and fewer adverse events were reported. Overall, patients in the combination group expressed higher satisfaction with their treatment. Hence, Montelukast + Levocetirizine is a more beneficial option for managing the symptoms of perennial AR in pediatrics, offering both superior symptom control and quality of life.
Allergy, Asthma & Immunology Research
Efficacy and Safety of Montelukast+Levocetirizine Combination Therapy Compared to Montelukast Monotherapy for Allergic Rhinitis in Children
Chang-Keun Kim et al.
Comments (0)